LINC01976: A Long Intergenic Non-Protein Coding RNA as a Drug Target and Biomarker

Target Name: LINC01976

NCBI ID: G107546764

LINC01976

Other Name(s): long intergenic non-protein coding RNA 1976 | Long intergenic non-protein coding RNA 1976

LINC01976: A Long Intergenic Non-Protein Coding RNA as a Drug Target and Biomarker

LINC01976 is a long intergenic non-protein coding RNA (lncRNA) that has been identified as a potential drug target and biomarker. It is a non-coding RNA molecule that is located between the genes HSP70 and HSP90, which are involved in the folding and stability of proteins. HSP70 and HSP90 are known as heat shock proteins (HSPs) and are expressed in a variety of tissues and cells, including the brain, muscle, and blood cells. HSPs have been implicated in a wide range of biological processes, including stress response, protein folding, and cell survival.

The discovery of LINC01976

The LINC01976 gene was identified using transcriptomics techniques, such as RNA sequencing (RNA-seq). RNA-seq is a powerful tool that allows researchers to identify and quantify RNA molecules in a sample. In the case of LINC01976, RNA-seq experiments revealed that the gene was expressed in a variety of tissues and cells, including the brain, heart, and liver. The gene was also shown to be expressed in adult stem cells, which are a type of cell that have the ability to develop into any cell in the body.

The function of LINC01976

The function of LINC01976 is not yet fully understood, but it is believed to play a role in the regulation of protein folding and stability. HSPs are known to play a critical role in protein folding and stability, as they can interact with other proteins and help to ensure that they are properly processed and function correctly. LINC01976 is thought to be involved in this process, as it has been shown to interact with HSP70 and HSP90.

Drug targeting and biomarker potential

The potential drug targeting of LINC01976 is based on its involvement in the regulation of protein folding and stability. Many drugs work by modulating the activity of proteins, either by binding to a specific protein or by inhibiting its activity altogether. LINC01976 could be a drug target by modulating the activity of HSPs, which could potentially lead to a wide range of therapeutic benefits.

In addition to its potential as a drug target, LINC01976 also has potential as a biomarker. The expression of LINC01976 has been shown to be associated with a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This suggests that LINC01976 could be a useful biomarker for these diseases, as it could be potential therapeutic targets.

Conclusion

LINC01976 is a long intergenic non-protein coding RNA that has been shown to interact with HSP70 and HSP90, which are involved in the regulation of protein folding and stability. Its potential as a drug target and biomarker is based on its involvement in these processes, as well as its expression in a variety of tissues and cells. Further research is needed to fully understand the function of LINC01976 and its potential as a therapeutic or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1976

The "LINC01976 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01976 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets